跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ZABDENO SUSPENSION INYECTABLE - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
ZABDENO SUSPENSION INYECTABLE
Approved
STANDARD
ZABDENO SUSPENSION INYECTABLE
Janssen-Cilag International N.V
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
May 25, 2021
Approval ID
1d16243080964007
Company
Janssen-Cilag International N.V
Type
Standard
Approval Details
Approval Id
1d16243080964007
Drug Cima Aemps Name
ZABDENO SUSPENSION INYECTABLE
Register Number
1201444001
Holder Company Name
Janssen-Cilag International N.V
Marketing Company Name
Janssen Cilag S.A.
Holder Company Detail Path
/organization/janssen-cilag-international-nv
Authorization Date
2021-05-25
Dosage Form
SUSPENSIÓN INYECTABLE
Dose
0,50 ml
Route Of Administration
VÍA INTRAMUSCULAR
Prescription Type
Uso Hospitalario
Commercialized
No
Company Name
Janssen-Cilag International N.V
Company Detail Path
/organization/janssen-cilag-international-nv
Company Information
Pharmaceutical Company Name
Janssen-Cilag International NV
Country Name
Belgium
Active Ingredients
VECTOR ADENOVIRUS DE TIPO 26 (AD26) QUE CODIFICA LA GLUCOPROTEINA (GP) DE LA VARIANTE MAYINGA DE ZAIRE EBOLAVIRUS
8,75 log10 unidades infecciosas (Inf.U)
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
May 25, 2021
Approval ID
1d16243080964007
Type
Standard
Back to CIMA-AEMPS Approvals